Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain

Diabetes Research and Clinical Practice

Volumn 93, Issue 2, 2011, Pages 187-197

  Webster, Lynn R ^a   Peppin, John F ^b   Murphy, Frederick T ^c   Lu, Biao ^d   Tobias, Jeffrey K ^d   Vanhove, Geertrui F ^d  

^a Lifetree Clinical Research and Pain Clinic   (United States)

^b The Pain Treatment Center of the Bluegrass   (United States)

^c Altoona Center for Clinical Research   (United States)

^d NeurogesX Inc   (United States)

Author keywords

Capsaicin patch; Painful diabetic neuropathy; Peripheral neuropathic pain; Postherpetic neuralgia

Indexed keywords

CAPSAICIN; CYCLOMETHYCAINE; LIDOCAINE;

ADULT; ADVERSE OUTCOME; APPLICATION SITE BURNING; APPLICATION SITE DISCOMFORT; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOT ULCER; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; OPEN STUDY; PAIN ASSESSMENT; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; SENSORY ANALYSIS; SENSORY DYSFUNCTION; SKIN EXAMINATION; SKIN IRRITATION; TRANSDERMAL PATCH; TREATMENT DURATION; VITAL SIGN;

AGED; ANESTHETICS, LOCAL; CAPSAICIN; DIABETIC NEUROPATHIES; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYNEUROPATHIES; SENSORY SYSTEM AGENTS; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 80051574246     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.04.010     Document Type: Article

References (48)

1. Treede R.D., Jensen T.S., Campbell J.N., Cruccu G., Dostrovsky J.O., Griffin J.W., et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008, 70(18):1630-1635.
2. Harden N., Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003, 25(Suppl 5):S12-S17.
3. Dworkin R.H., Gnann J.W., Oaklander A.L., Raja S.N., Schmader K.E., Whitley R.J., et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008, 9(Suppl 1):S37-S44.
4. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354.
5. Johnson R.W., Dworkin R.H. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003, 326:748-750.
6. Gauthier A., Breuer J., Carrington D., Martin M., Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137(1):38-47.
7. Barrett A.M., Lucero M.A., Le T., Robinson R.L., Dworkin R.H., Chappell A.S., et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007, 8(Suppl 2):S50-S62.
8. Boulton A.J.M., Malik R.A., Arezzo J.C., Sosenko J.M. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
9. Boulton A.J.M., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Malik R.A., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
10. Spruce M.C., Potter J., Coppini D.V. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003, 20(2):88-98.
11. Young M.J., Boulton A.J., Maclead A.F., Williams D.R., Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150-154.
12. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006, 66:1679-1687.
13. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000, 59:1251-1260.
14. Attal N., Cruccu G., Baron R., Haanpää M., Hansson P., Jensen T.S., et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010, 17(9). 1113-e 88.
15. Cruccu G., Aziz T.Z., Garcia-Larrea L., Hansson P., Jensen T.S., Lefaucheur J.P., et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007, 14:952-970.
16. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
17. Moulin D.E., Clark A.J., Gilron I., Ware M.A., Watson C.P., Sessie B.J., et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12:13-21.
18. Jackson K.C. Pharmacotherapy for neuropathic pain. Pain Pract 2006, 6:27-33.
19. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389-400.
20. Facer P., Casula M.A., Smith G.D., Benham C.D., Chessell I.P., Bountra C., et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 2007, 7:11.
21. Wilder-Smith E.P., Ong W.Y., Guo Y., Chow A.W. Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human patients. Histopathology 2007, 51:674-680.
22. Cortright D.N., Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004, 271:1814-1819.
23. Szallasi A., Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999, 51:159-212.
24. Bley K.R. TRPV1 agonist approaches for pain management. Vanilloid receptor TRPV1 in drug discovery: medicinal chemistry, biology, and therapeutic potential for chronic pain and pathological disorders 2010, 325-347. John Wiley & Sons, New York. A. Gomtsyan, C.R. Faltynek (Eds.).
25. Derry S., Lloyd R., Moore R.A., McQuay H.J. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009, 4:CD007393.
26. Mason L., Moore R.A., Derry S., Edwards J.E., McQuay H.J. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004, 328(7446):991.
27. Paice J.A., Ferrans C.E., Lashley F.R., Shott S., Vizgirda V., Pitrak D., et al. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 2000, 19(1):45-52.
28. Noto C., Pappagallo M., Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Invest Drugs 2009, 10(7):702-710.
29. Simpson D.M., Estanislao L., Brown S.J., Sampson J. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage 2008, 35:299-306.
30. Simpson D.M., Brown S., Tobias J. A trial of a high-concentration capsaicin patch for the treatment of painful HIV neuropathy. Neurology 2008, 70:2305-2313.
31. Backonja M., Wallace M.S., Blonsky E.R., Cutler B.J., Malan P., Rauck R., et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008, 7:1106-1112.
32. Backonja M.M., Malan T.P., Vanhove G.F., Tobias J.K., for the C102/106 Study Group NGX-4010. A high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 2010, 11:600-608.
33. Irving G.A., Backonja M., Dunteman E., Blonsky E.R., Vanhove G.F., Lu S.P., et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011, 12:99-109.
34. Webster L.R., Peppin J.F., Murphy F.T., Tobias J.K., Vanhove G.R. Tolerability of NGX-4010 in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. Pain Med 2010, 11:323-324.
35. Farrar J.T., Young J.P., LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
36. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products. Washington, DC: US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research; 1999. Available from: [accessed 15.09.10]. http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf%23search=%2522HillTop%2520Research%252C%2520Inc.%2520dermal%2520irritation%2522.
37. Simpson D., Brown S., Tobias J., the C107 Study Team Treatment of painful HIV-associated distal sensory polyneuropathy (DSP) with a high-concentration capsaicin dermal patch (NGX-4010): report of a 52-week study. Neurology 2007, 68(12 Suppl 1):A346-A347.
38. Webster L.R., Malan T.P., Tuchman M.M., Mollen M.D., Tobias J.K., Lu B., et al. Duration of treatment response to NGX-4010, a high-concentration capsaicin patch, in patients with postherpetic neuralgia. J Pain 2010, 11(4):S51.
39. Simpson D.M., Gazda S., Brown S., Webster L.R., Lu S.P., Tobias J.K., et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 2010, 39:1053-1064.
40. Malmberg A.B., Mizisin A.P., Calcutt N.A., von Stein T., Robbins W.R., Bley K.R., et al. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 2004, 111:360-367.
41. Kennedy W.R., Vanhove G.F., Lu S.-P., Tobias J., Bely K.R., Walk D., et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010, 11:579-587.
42. The Capsaicin Study Group Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991, 151(11):2225-2229.
43. Tandan R., Lewis G.A., Krusinski P.B., Badger G.B., Fries T.J. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992, 15(1):8-14.
44. Biesbroeck R., Bril V., Hollander P., Kabadi U., Schwartz S., Singh S.P., et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995, 12(2):111-120.
45. Forst T., Pohlmann T., Kunt T., Goitom K., Schulz G., Löbig M., et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002, 39(1):1-6.
46. Henriksson F., Agardh C.D., Berne C., Bolinder J., Lönnqvist F., Stenström P., et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000, 248(5):387-396.
47. Ndip A., Jude E.B. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. Int J Low Extrem Wounds 2009, 8(2):82-94.
48. Abbott C.A., Vileikyte L., Williamson S., Carrington A.L., Boulton A.J. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998, 21(7):1071-1075.